Comparison Of European Medicines Agency (EMA) And Food And Drug Administration (FDA) Procedures For Evaluating Scientific And Regulatory Issues Of Clinical Studies During The Development Of Medicinal Products: Experience Of A Global Imaging Clinical Research Organization | 7536
Pharmaceutical Regulatory Affairs: Open Access
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Comparison of European Medicines Agency (EMA) and Food and Drug Administration (FDA) procedures for evaluating scientific and regulatory issues of clinical studies during the development of medicinal products: Experience of a global imaging clinical research organization
2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs
Here we compare the procedures for obtaining pre-approval for the Clinical Study Protocols and accompanying documentation
by two regulatory agencies - European Medicines Agency (EMA) and Food and Drug Administration (FDA). The procedures
called Scientific Advice and Protocol Assistance (SA/PA), and Special Protocol Assessment (SPA), respectively, are compared in
terms of duration, scope, cost and possible outcomes. In addition, we discuss the reasons why our clients submitted more than
fifty Independent Review Charters (IRC, a document which governs the independent review process) as accompanying material
for SPA to FDA, and to our knowledge none for SA/PA to EMA. Research of publicly available documents and company-wide
investigation showed that the two procedures are similar in design and purpose. If the sponsor and the agency agree on the
design, execution and analyses proposed in the submitted documentation, the agreement becomes part of the administrative
record. The agreement is not legally binding on either of the Agencies; however, complying with the agreement significantly
shortens the duration of the marketing authorization applications and increases its success. Our data show that pre-approval
procedures, if employed, offer a clear benefit to clients; therefore they should be explained and recommended to all clients
targeting global markets.
Katarina Ludajic is a Senior Medical Writer at Perceptive Informatics. She earned a B.S. in Biology at the University of Belgrade, Serbia and Ph.D.
in Molecular Biology at the Friedrich-Schiller University in Jena, Germany. She has completed her post-doctoral training at the General Hospital of
Vienna, Austria where she performed research in the field of Transplantation Biology. She is the first author on multiple scientific articles published
in peer-reviewed journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals